Multiple Sclerosis and the Evolution of its Treatments
Main Article Content
Abstract
Multiple sclerosis is an autoimmune disease that demyelinates the nerves, the damage to the nerves interrupts communication between the brain and the body. Although it is a disease that has no cure, it has been studied for a long time to try to find a treatment to stop the progression of the disease. Currently there are many drugs that can help reduce the effects caused by the disease, but it is necessary to evaluate which one is given because of the adverse effects that these may have, even so, the research of new treatments has not stopped until finding one that benefits completely or its risks are minimal.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Cree, B. A., & Hauser, S. L. (2016). GSU digital library. Retrieved from AccessMedicine https://bibliodig.uag.mx:2074/content.aspx?sectionid=267807982&bookid=31 18&Resultcli ck=2
II. Fernandez, J. (March 31, 2022). Baptist Health South Florida. Retrieved from https://baptisthealth.net/baptist-health-news/es/la-esclerosis-multiple-los-ava nces-in-therapies-and-research-can-reduce-the-progression-of-the-e m-and-potentially-prevent-disease/
III. García, C. C. (August 29, 2022). Government of Mexico. Retrieved from
https://www.gob.mx/imss/articulos/esclerosis-multiple-la-enfermedad-de-las- mil-caras
IV. Marínez-Altarriba, M. (September 2015). Elsevier. Retrieved from Medicina de Medicina deFamilia. SEMERGEN: https://www.elsevier.es/es-revista-medicina-familia-semergen-40-articulo-revision-esclerosis-multiple-2-diagnostico-S1138359314003256
V. Torres, P. C. (2015). Special communication in neurology. Retrieved from
http://www.scielo.org.co/pdf/anco/v31n1/v31n1a17.pdf
VI. Darwin R, (2019).Clinical Practice Guideline for the Diagnosis and Treatment of Multiple Sclerosis in Adults.https://doi.org/10.20453/rnp.v82i4.3646
VII. .Boullosa-Lale S, González-Freire L, Martínez-Martínez L, Crespo-Diz C. Safety and persistence of dimethyl fumarate as a treatment for relapsing-remitting multiple sclerosis. Farm Hosp. 2021;45(2):73-6. DOI: 10.7399/fh.11567.
VIII. .López Gutiérrez, C.R., Castrillón Taba, M., & Lopera Vásquez, J.P. (2022). Effect of a neuropsychological rehabilitation program of executive functions in a case of multiple sclerosis. Rev. CES Psico, 15(3), 97-114.
https://dx.doi.org/10.21615/cesp.6104
IX. .Karen Whalen (2016). Pharmacology, sixth edition, wolters Kluwer publishing house.
X. Arteaga-Noriega A. (2020) Symptomatological treatment of multiple sclerosis. Revistaavft.com. Available at:
https://www.revistaavft.com/images/revistas/2020/avft_2_2020/1_trataiento_s intomatol%C3%B3gico.pdf.
XI. Mrabet, S., Wafa, M., & Giovannoni, G. (2022). Multiple sclerosis and migraine: Links, management and implications. Multiple Sclerosis and Related Disorders, 68(104152), 104152. https://doi.org/10.1016/j.msard.2022.104152.
XII. Kyriakatis, G. M., Besios, T., & Lykou, P. M. (2022). The effect of therapeutic exercise on depressive symptoms in people with multiple sclerosis - A systematic review. Multiple Sclerosis and Related Disorders, 68(104407), 104407. https://doi.org/10.1016/j.msard.2022.104407.
XIII. Harrison. Principles of Internal Medicine, 21e. (2022). Mhmedical.com. Retrieved April 19, 2023, from https://accessmedicina.mhmedical.com/book.aspx?bookID=3118